Join
Ethos Technologies Inc. logo

LIFE

NASDAQ

Ethos Technologies Inc.

SectorFinanceIndustrySpecialty InsurersIPO2026
News25/Ratings12

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Price$16.68-0.50 (-2.91%)
01:30 PM07:15 PM
News · 26 weeks69-50%
2025-12-14: 02025-12-21: 02025-12-28: 02026-01-04: 02026-01-11: 02026-01-18: 22026-01-25: 292026-02-01: 62026-02-08: 02026-02-15: 02026-02-22: 122026-03-01: 02026-03-08: 02026-03-15: 02026-03-22: 12026-03-29: 12026-04-05: 02026-04-12: 02026-04-19: 12026-04-26: 02026-05-03: 52026-05-10: 62026-05-17: 62026-05-24: 02026-05-31: 02026-06-07: 0
2025-12-142026-06-07
Mix2090d
  • Other7(35%)
  • SEC Filings5(25%)
  • Insider5(25%)
  • Offering2(10%)
  • Earnings1(5%)

Latest news

25 items

LIFE FAQ

7 questions
  • What does Ethos Technologies Inc. do?
    aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized...
  • Where does LIFE stock trade?
    Ethos Technologies Inc. (LIFE) is listed on NASDAQ.
  • What sector and industry is LIFE in?
    Ethos Technologies Inc. operates in the Finance sector, Specialty Insurers industry.
  • When did Ethos Technologies Inc. go public?
    Ethos Technologies Inc. (LIFE) completed its IPO in 2026.
  • What are analysts saying about LIFE?
    Ethos Technologies Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy with a $3300.00 price target on 2026-02-23. Recent price targets range from $1300.00 to $3300.00.
  • What companies are similar to LIFE?
    Notable peers in the same industry include MEIP (MEI Pharma Inc.), EPIX (ESSA Pharma Inc.), EVOK (Evoke Pharma Inc.). Compare LIFE side-by-side with any of them on Quantisnow.
  • How can I track LIFE on Quantisnow?
    Quantisnow aggregates Ethos Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LIFE to receive live email and push alerts on every new disclosure.